Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeResource RepositoryNext-generation humanized NKG mouse platforms enable pharmacodynamic and antitumor evaluation of in vivo CAR therapies
Poster

Next-generation humanized NKG mouse platforms enable pharmacodynamic and antitumor evaluation of in vivo CAR therapies

Evaluating two complementary humanized NKG mouse platforms for preclinical testing of in vivo CAR therapies. huHSC-NKG-ProF mice supported longitudinal pharmacodynamic assessment of CD19-targeting CAR-mediated B-cell depletion, while T-cell-rich huPBMC-NKG mice enabled rapid antitumor evaluation of LNP-delivered BCMA-targeting CAR in a multiple myeloma xenograft model.
Next-generation humanized NKG mouse platforms enable pharmacodynamic  and antitumor evaluation of in vivo CAR therapies

Overview

In vivo CAR therapies generate CAR-expressing immune cells directly in the patient, but their translation requires humanized preclinical models that capture CAR generation, pharmacodynamics, and efficacy. We assessed two humanized NKG platforms. huHSC-NKG-ProF mice achieved >25% human CD45+ engraftment from 12 weeks with stable multilineage reconstitution (T, B, NK, myeloid) across three donors; a single CD19-targeting lentiviral in vivo CAR dose produced rapid, sustained peripheral B-cell depletion through Day 56. huPBMC-NKG mice reconstituted ~50% human CD45+ cells, ~95% CD3+ T cells; LNP-delivered BCMA-targeting CAR gave 62% tumor growth inhibition in NCI-H929 xenografts, with CAR+ cells in ~42% of human CD8+ T cells.

Key Insights

Two complementary humanized NKG mouse models — multilineage huHSC-NKG-ProF and T-cell-rich huPBMC-NKG — provide fit-for-purpose platforms for evaluating the pharmacodynamics and antitumor efficacy of in vivo CAR therapies.
  • Durable multilineage humanization for longitudinal studies. huHSC-NKG-ProF mice sustained >25% human CD45+ engraftment from week 12 onward with low inter-donor variability across three HSC cohorts, reconstituting CD3+ T, CD19+ B, CD56+ NK, and CD33+ myeloid lineages.
  • Clear pharmacodynamic readout for B-cell-directed CAR. A single intravenous dose of CD19-targeting in vivo CAR lentivirus drove rapid and sustained peripheral B-cell depletion through the full 56-day window, while total human leukocyte levels remained stable
  • Rapid efficacy model with measurable CAR generation. In T-cell-rich huPBMC-NKG mice bearing BCMA+ NCI-H929 xenografts, LNP-delivered in vivo CAR achieved 62% tumor growth inhibition with CAR expression in ~42% of human CD8+ T cells and no notable body-weight loss.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Download Details
Full Name
Email
Organization
Job Role
Country
Main Area of Research
Resource Preferences
Which type of solutions are you considering?
Do you plan to start a project with us within the next 6 months?
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research